RYALTRIS® is a fixed-dose combination nasal spray developed for the treatment of seasonal allergic rhinitis in patients 12 years of age and older. Unlike single-agent therapies, it provides relief for both nasal and ocular symptoms, addressing congestion, sneezing, rhinorrhea, itching, as well as itchy, watery, and red eyes. This dual benefit offers patients more complete symptom control during allergy season.
Each spray contains two active components: olopatadine hydrochloride, a fast-acting antihistamine, and mometasone furoate, an established corticosteroid. Together, these agents deliver both rapid onset of action and sustained symptom relief.
Key areas of functionality include:
- Relief of both nasal and ocular allergy symptoms
- Dual-mechanism combination: antihistamine + corticosteroid
- Rapid onset with sustained efficacy
- Convenient twice-daily dosing regimen
Clinical efficacy was demonstrated in two multicenter, randomized, double-blind, placebo- and active-controlled studies involving over 2,300 patients. RYALTRIS® achieved statistically significant improvements in nasal and ocular symptom scores compared with placebo, with results observed throughout the 14-day treatment period.
